Viracta Therapeutics: Funding, Investors & Team (Oct 2026)
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
Viracta Therapeutics has raised $50.0M across 1 funding round on record, the most recent a Post-IPO Debt of $50.0M announced in Nov 2021.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Viracta Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2021.
Viracta Therapeutics Funding Rounds
Viracta Therapeutics Founders and Leadership Team
Contact details for the Viracta Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Viracta Therapeutics Funding Compared to Other Biotechnology Startups
Viracta Therapeutics' latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Viracta Therapeutics in Biotechnology and Cardiff By The Sea
Companies Similar to Viracta Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Viracta Therapeutics Funding FAQs
What does Viracta Therapeutics do?
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
How much funding has Viracta Therapeutics raised?
Viracta Therapeutics has raised $50.0M across 1 round on record. The most recent is a Post-IPO Debt of $50.0M announced in Nov 2021.
When did Viracta Therapeutics last raise funding?
Viracta Therapeutics' most recent funding round on record is a Post-IPO Debt of $50.0M, announced in Nov 2021.
Who is the CEO of Viracta Therapeutics?
Ivor Royston is listed as CEO at Viracta Therapeutics.
Where is Viracta Therapeutics headquartered?
Viracta Therapeutics is based in Cardiff By The Sea, California, United States.
How many employees does Viracta Therapeutics have?
Viracta Therapeutics is in the 11-50 employee band.
How does Viracta Therapeutics' funding compare to other Biotechnology startups?
Viracta Therapeutics' latest round of $50.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Viracta Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Viracta Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.